Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04167670 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection
A Phase 3 study, sponsored by Phathom Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,046
- Enrollment target
NCT04167670 is a Phase 3 study that has completed, run by Phathom Pharmaceuticals. The registered enrollment target is 1,046 participants.
The verdict
NCT04167670, a Phase 3 study, has completed, sponsored by Phathom Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,046 participants
- Enrollment target
Study Summary
To compare the efficacy of Helicobacter pylori (HP) eradication with vonoprazan dual and triple therapy regimens versus lansoprazole triple therapy regimen in participants with HP infection, excluding participants who had a clarithromycin or amoxicillin resistant strain of HP at baseline.
Interventions
- DRUG Amoxicillin
- DRUG Vonoprazan
- DRUG Clarithromycin
- DRUG Lansoprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,046 participants |
| Start Date | 2019-12-10 |
| Est. Completion | 2021-03-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04167670
The ClinicalTrials.gov registry entry for NCT04167670 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,046 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Phathom Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Amoxicillin is the first listed.
NCT04167670 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04167670 about?
NCT04167670 is a clinical study titled "Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection". To compare the efficacy of Helicobacter pylori (HP) eradication with vonoprazan dual and triple therapy regimens versus lansoprazole triple therapy regimen in participants with HP infection, excluding participants who had a clarithromycin or amoxicillin resistant strain of HP at baseline.
What is the current status of trial NCT04167670?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,046 participants. The study started on 2019-12-10. Estimated completion is 2021-03-18.
What interventions are being tested in trial NCT04167670?
The interventions under investigation include: Amoxicillin (DRUG), Vonoprazan (DRUG), Clarithromycin (DRUG), Lansoprazole (DRUG).
Who is sponsoring clinical trial NCT04167670?
This trial is sponsored by Phathom Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.